Evidence map›Paper›PMID 11483779›Full record

ArticleJournal of virology2001

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

P W Parren, P A Marx, A J Hessell, A Luckay, J Harouse, C Cheng-Mayer, J P Moore, D R Burton

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 401 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
401citing papers in PubMed, 1 pooled it
8.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

401 citing papers in PubMed, 1 synthesis or guideline pooled it, 659 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

341 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

P W ParrenDepartments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
P A Marx
A J Hessell
A Luckay
J Harouse
C Cheng-Mayer
J P Moore
D R Burton
Scripps Research Institute · USRockefeller University · USAaron Diamond AIDS Research Center · USCornell University · USTulane University · US

Funding

VPA 985 IN LIVER CIRRHOSIS &ASCITESM01RR000833 · NCRR · SCRIPPS RESEARCH INSTITUTE · PI BABIOR, BERNARD M · 1985 to 2004
$14.0M
NEUTRALIZATION OF PRIMARY HIV1 VIRUSESR37AI036082 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 1998 to 2017
$7.0M
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONINGR01AI033292 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 1992 to 2013
$5.9M
Neutralization of Primate Immunodeficiency VirusesR01AI036082 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JOHN P MOORE · 1994 to 2026
$4.3M
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONINGR37AI033292 · NIAID · SCRIPPS RESEARCH INSTITUTE · PI BURTON, DENNIS R. · 1995 to 2004
$2.4M
PROGESTERONE &ESTROGEN EFFECTS--SIV VAGINAL TRANSMISSR01AI041952 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI MARX, PRESTON A · 1997 to 2007
$2.1M
ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPPL-SCID MICER01HL059727 · NHLBI · SCRIPPS RESEARCH INSTITUTE · PI BURTON, DENNIS R. · 1997 to 2001
$1.1M
HIV NEUTRALIZATION IN VITRO &IN SHIV-INFECTED MACAQUESR01HL059735 · NHLBI · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI MOORE, JOHN P · 1997 to 2001
$591k
ANTIBODY FC AND HIV-1 INACTIVATIONR29AI040377 · NIAID · SCRIPPS RESEARCH INSTITUTE · PI PARREN, PAUL W · 1996 to 2000
$125k
NCRR NIH HHS M01 RR000833NHLBI NIH HHS HL59727NHLBI NIH HHS HL59735NIAID NIH HHS AI33292NIAID NIH HHS AI36082NIAID NIH HHS AI40377NIAID NIH HHS AI 41952NIAID NIH HHS R01 AI033292NIAID NIH HHS R01 AI036082NIAID NIH HHS R01 AI041952NIAID NIH HHS R37 AI033292NIAID NIH HHS R37 AI036082
6 · The paper itself

Abstract

A major unknown in human immunodeficiency virus (HIV-1) vaccine design is the efficacy of antibodies in preventing mucosal transmission of R5 viruses. These viruses, which use CCR5 as a coreceptor, appear to have a selective advantage in transmission of HIV-1 in humans. Hence R5 viruses predominate during primary infection and persist throughout the course of disease in most infected people. Vaginal challenge of macaques with chimeric simian/human immunodeficiency viruses (SHIV) is perhaps one of the best available animal models for human HIV-1 infection. Passive transfer studies are widely used to establish the conditions for antibody protection against viral challenge. Here we show that passive intravenous transfer of the human neutralizing monoclonal antibody b12 provides dose-dependent protection to macaques vaginally challenged with the R5 virus SHIV(162P4). Four of four monkeys given 25 mg of b12 per kg of body weight 6 h prior to challenge showed no evidence of viral infection (sterile protection). Two of four monkeys given 5 mg of b12/kg were similarly protected, whereas the other two showed significantly reduced and delayed plasma viremia compared to control animals. In contrast, all four monkeys treated with a dose of 1 mg/kg became infected with viremia levels close to those for control animals. Antibody b12 serum concentrations at the time of virus challenge corresponded to approximately 400 (25 mg/kg), 80 (5 mg/kg), and 16 (1 mg/kg) times the in vitro (90%) neutralization titers. Therefore, complete protection against mucosal challenge with an R5 SHIV required essentially complete neutralization of the infecting virus. This suggests that a vaccine based on antibody alone would need to sustain serum neutralizing antibody titers (90%) of the order of 1:400 to achieve sterile protection but that lower titers, around 1:100, could provide a significant benefit. The significance of such substerilizing neutralizing antibody titers in the context of a potent cellular immune response is an important area for further study.

Indexed as

Immunization, PassiveAdministration, IntravaginalAnimalsAntibodies, MonoclonalFemaleHIVHIV AntibodiesHIV InfectionsHumansImmunoglobulin GMacacaNeutralization TestsRNA, ViralSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVaginal DischargeAntibodies, MonoclonalHIV AntibodiesImmunoglobulin GRNA, Viral

Identifiers

PMID11483779
PMCPMC115078
OpenAlexW2065329551

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.